The analysis of FSCN1 using immunohistochemistry in prostate carcinoma glands found that only 8% of PCa had more than 10% FSCN1 positivity; FSCN1 expression, however, did not correlate with Gleason score, tumor stage, serum PSA levels or biochemical relapse following surgery [43]. Here, FSCN1 is linked to posterior cortical atrophy.